Restoration of chemosensitivity by bortezomib: implications for refractory myeloma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-04

AUTHORS

Chor Sang Chim, Yu Yan Hwang, Clara Pang, Tony W. Shek

ABSTRACT

Resistance to chemotherapy remains one of the major challenges in the treatment of patients with multiple myeloma. Chim et al. report the case of a 59-year-old woman with multiple myeloma, who progressed after treatment with conventional chemotherapeutic agents. Addition of bortezomib to her treatment regimen resulted in complete regression of her disease. The authors suggest that bortezomib can restore chemosensitivity of myeloma cells in heavily pretreated, chemorefractory patients with multiple myeloma. More... »

PAGES

237-240

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.15

DOI

http://dx.doi.org/10.1038/nrclinonc.2009.15

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036375929

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19333230


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Boronic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bortezomib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protease Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.415550.0", 
          "name": [
            "Department of Medicine, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chim", 
        "givenName": "Chor Sang", 
        "id": "sg:person.0722115232.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722115232.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.415550.0", 
          "name": [
            "Department of Medicine, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hwang", 
        "givenName": "Yu Yan", 
        "id": "sg:person.01123355430.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123355430.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.415550.0", 
          "name": [
            "Department of Radiology, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pang", 
        "givenName": "Clara", 
        "id": "sg:person.01264340572.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264340572.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Queen Mary Hospital, Hong Kong", 
          "id": "http://www.grid.ac/institutes/grid.415550.0", 
          "name": [
            "Department of Pathology, Queen Mary Hospital, Hong Kong"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shek", 
        "givenName": "Tony W.", 
        "id": "sg:person.01034356570.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034356570.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrc2189", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006747668", 
          "https://doi.org/10.1038/nrc2189"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1704713", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010241768", 
          "https://doi.org/10.1038/sj.bmt.1704713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012096528", 
          "https://doi.org/10.1038/nrc746"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-04", 
    "datePublishedReg": "2009-04-01", 
    "description": "Resistance to chemotherapy remains one of the major challenges in the treatment of patients with multiple myeloma. Chim et al. report the case of a 59-year-old woman with multiple myeloma, who progressed after treatment with conventional chemotherapeutic agents. Addition of bortezomib to her treatment regimen resulted in complete regression of her disease. The authors suggest that bortezomib can restore chemosensitivity of myeloma cells in heavily pretreated, chemorefractory patients with multiple myeloma.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/nrclinonc.2009.15", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1034153", 
        "issn": [
          "1759-4774", 
          "1759-4782"
        ], 
        "name": "Nature Reviews Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "keywords": [
      "multiple myeloma", 
      "addition of bortezomib", 
      "treatment of patients", 
      "conventional chemotherapeutic agents", 
      "chemorefractory patients", 
      "refractory myeloma", 
      "treatment regimen", 
      "complete regression", 
      "restoration of chemosensitivity", 
      "myeloma", 
      "chemotherapeutic agents", 
      "myeloma cells", 
      "bortezomib", 
      "patients", 
      "chemosensitivity", 
      "treatment", 
      "regimen", 
      "chemotherapy", 
      "disease", 
      "women", 
      "cells", 
      "regression", 
      "agents", 
      "cases", 
      "restoration", 
      "CHIM", 
      "major challenge", 
      "resistance", 
      "addition", 
      "implications", 
      "authors", 
      "challenges", 
      "al"
    ], 
    "name": "Restoration of chemosensitivity by bortezomib: implications for refractory myeloma", 
    "pagination": "237-240", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036375929"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/nrclinonc.2009.15"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19333230"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/nrclinonc.2009.15", 
      "https://app.dimensions.ai/details/publication/pub.1036375929"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_488.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/nrclinonc.2009.15"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.15'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.15'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.15'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrclinonc.2009.15'


 

This table displays all metadata directly associated to this object as RDF triples.

187 TRIPLES      21 PREDICATES      76 URIs      65 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/nrclinonc.2009.15 schema:about N025ab44c7cfc4166ac60bfb3b2032b2f
2 N0b11283547c84338bd9355ba47fc0d42
3 N19148092ee6744949f0ee871d51e3b09
4 N206fa12c990146bf88c9d92d96939765
5 N47e7ef55c4a743c0a77e87d3f5c06513
6 N53a050eb3911440cbdf854c6f6827fb6
7 N5881410194df48c7a0c1029eed24aa7b
8 N635fdc2f68764a79ae847f2b569e4af3
9 N7a2ad2c1192d4f5c93d1c3e95730a5be
10 N895b5cc71302418eb545e3d651ebd5dd
11 Na9c733cb01684fc081bade568a55ee02
12 Nc2d351730c1b4a3e8666dc33f72a80a3
13 Ne2834469031c4a079fddc90a4b566a1b
14 Nff96c1997df44a759113cebaf6711e2b
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author Naaf812db2025459c9eae80f3342b62ad
18 schema:citation sg:pub.10.1038/nrc2189
19 sg:pub.10.1038/nrc746
20 sg:pub.10.1038/sj.bmt.1704713
21 schema:datePublished 2009-04
22 schema:datePublishedReg 2009-04-01
23 schema:description Resistance to chemotherapy remains one of the major challenges in the treatment of patients with multiple myeloma. Chim et al. report the case of a 59-year-old woman with multiple myeloma, who progressed after treatment with conventional chemotherapeutic agents. Addition of bortezomib to her treatment regimen resulted in complete regression of her disease. The authors suggest that bortezomib can restore chemosensitivity of myeloma cells in heavily pretreated, chemorefractory patients with multiple myeloma.
24 schema:genre article
25 schema:isAccessibleForFree false
26 schema:isPartOf N04724d3e414a48c890e90d2676a23673
27 N5b0121660abe48ffa5e71712a1c1e4f6
28 sg:journal.1034153
29 schema:keywords CHIM
30 addition
31 addition of bortezomib
32 agents
33 al
34 authors
35 bortezomib
36 cases
37 cells
38 challenges
39 chemorefractory patients
40 chemosensitivity
41 chemotherapeutic agents
42 chemotherapy
43 complete regression
44 conventional chemotherapeutic agents
45 disease
46 implications
47 major challenge
48 multiple myeloma
49 myeloma
50 myeloma cells
51 patients
52 refractory myeloma
53 regimen
54 regression
55 resistance
56 restoration
57 restoration of chemosensitivity
58 treatment
59 treatment of patients
60 treatment regimen
61 women
62 schema:name Restoration of chemosensitivity by bortezomib: implications for refractory myeloma
63 schema:pagination 237-240
64 schema:productId N93ba14236dc840c4a7423c9e952d1dab
65 Ne5d2a37cb90f4d6dbc7286c63e37b495
66 Nf85397c68de64f4c94d64bb12b1f6ff0
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036375929
68 https://doi.org/10.1038/nrclinonc.2009.15
69 schema:sdDatePublished 2022-12-01T06:27
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N9e983e4ada8e44ae8bc16bc4bc3c23e9
72 schema:url https://doi.org/10.1038/nrclinonc.2009.15
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N025ab44c7cfc4166ac60bfb3b2032b2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Pancreatic Neoplasms
78 rdf:type schema:DefinedTerm
79 N04724d3e414a48c890e90d2676a23673 schema:issueNumber 4
80 rdf:type schema:PublicationIssue
81 N0b11283547c84338bd9355ba47fc0d42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Pyrazines
83 rdf:type schema:DefinedTerm
84 N19148092ee6744949f0ee871d51e3b09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Antineoplastic Agents
86 rdf:type schema:DefinedTerm
87 N206fa12c990146bf88c9d92d96939765 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Female
89 rdf:type schema:DefinedTerm
90 N3f9befbbc4c147f18ca68b64963581d8 rdf:first sg:person.01264340572.14
91 rdf:rest Nf964f08347164864bbbe346917a68be3
92 N47e7ef55c4a743c0a77e87d3f5c06513 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Dose-Response Relationship, Drug
94 rdf:type schema:DefinedTerm
95 N53a050eb3911440cbdf854c6f6827fb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Pleural Neoplasms
97 rdf:type schema:DefinedTerm
98 N5881410194df48c7a0c1029eed24aa7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Multiple Myeloma
100 rdf:type schema:DefinedTerm
101 N5b0121660abe48ffa5e71712a1c1e4f6 schema:volumeNumber 6
102 rdf:type schema:PublicationVolume
103 N635fdc2f68764a79ae847f2b569e4af3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Bortezomib
105 rdf:type schema:DefinedTerm
106 N7a2ad2c1192d4f5c93d1c3e95730a5be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Boronic Acids
108 rdf:type schema:DefinedTerm
109 N895b5cc71302418eb545e3d651ebd5dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Treatment Outcome
111 rdf:type schema:DefinedTerm
112 N93ba14236dc840c4a7423c9e952d1dab schema:name dimensions_id
113 schema:value pub.1036375929
114 rdf:type schema:PropertyValue
115 N9e983e4ada8e44ae8bc16bc4bc3c23e9 schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 Na9c733cb01684fc081bade568a55ee02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Middle Aged
119 rdf:type schema:DefinedTerm
120 Naaf812db2025459c9eae80f3342b62ad rdf:first sg:person.0722115232.29
121 rdf:rest Nd8aa9545a26346faa23217e0e1bcaedb
122 Nc2d351730c1b4a3e8666dc33f72a80a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Drug Resistance, Neoplasm
124 rdf:type schema:DefinedTerm
125 Nd8aa9545a26346faa23217e0e1bcaedb rdf:first sg:person.01123355430.21
126 rdf:rest N3f9befbbc4c147f18ca68b64963581d8
127 Ne2834469031c4a079fddc90a4b566a1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Humans
129 rdf:type schema:DefinedTerm
130 Ne5d2a37cb90f4d6dbc7286c63e37b495 schema:name doi
131 schema:value 10.1038/nrclinonc.2009.15
132 rdf:type schema:PropertyValue
133 Nf85397c68de64f4c94d64bb12b1f6ff0 schema:name pubmed_id
134 schema:value 19333230
135 rdf:type schema:PropertyValue
136 Nf964f08347164864bbbe346917a68be3 rdf:first sg:person.01034356570.47
137 rdf:rest rdf:nil
138 Nff96c1997df44a759113cebaf6711e2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Protease Inhibitors
140 rdf:type schema:DefinedTerm
141 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
142 schema:name Medical and Health Sciences
143 rdf:type schema:DefinedTerm
144 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
145 schema:name Oncology and Carcinogenesis
146 rdf:type schema:DefinedTerm
147 sg:journal.1034153 schema:issn 1759-4774
148 1759-4782
149 schema:name Nature Reviews Clinical Oncology
150 schema:publisher Springer Nature
151 rdf:type schema:Periodical
152 sg:person.01034356570.47 schema:affiliation grid-institutes:grid.415550.0
153 schema:familyName Shek
154 schema:givenName Tony W.
155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034356570.47
156 rdf:type schema:Person
157 sg:person.01123355430.21 schema:affiliation grid-institutes:grid.415550.0
158 schema:familyName Hwang
159 schema:givenName Yu Yan
160 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123355430.21
161 rdf:type schema:Person
162 sg:person.01264340572.14 schema:affiliation grid-institutes:grid.415550.0
163 schema:familyName Pang
164 schema:givenName Clara
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264340572.14
166 rdf:type schema:Person
167 sg:person.0722115232.29 schema:affiliation grid-institutes:grid.415550.0
168 schema:familyName Chim
169 schema:givenName Chor Sang
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722115232.29
171 rdf:type schema:Person
172 sg:pub.10.1038/nrc2189 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006747668
173 https://doi.org/10.1038/nrc2189
174 rdf:type schema:CreativeWork
175 sg:pub.10.1038/nrc746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012096528
176 https://doi.org/10.1038/nrc746
177 rdf:type schema:CreativeWork
178 sg:pub.10.1038/sj.bmt.1704713 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010241768
179 https://doi.org/10.1038/sj.bmt.1704713
180 rdf:type schema:CreativeWork
181 grid-institutes:grid.415550.0 schema:alternateName Department of Medicine, Queen Mary Hospital, Hong Kong
182 Department of Pathology, Queen Mary Hospital, Hong Kong
183 Department of Radiology, Queen Mary Hospital, Hong Kong
184 schema:name Department of Medicine, Queen Mary Hospital, Hong Kong
185 Department of Pathology, Queen Mary Hospital, Hong Kong
186 Department of Radiology, Queen Mary Hospital, Hong Kong
187 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...